Real-world, digital-first delivery of GLP-1 receptor agonist therapy in women
Study population Between 27 November 2024 and 31 January 2025, adult women (female sex at birth) were recruited…
Performance and safety of a multi-cancer early detection test: the PATHFINDER 2 study
Ethical approval and consent This study was performed in accordance with the Declaration of Helsinki. All study procedures…
Vitamin B12 absorption and factors associated with the response to long-term oral B12 supplementation: a secondary analysis of data from a B12-deficient Indian rural community
Allen LH, Miller JW, de Groot L, Rosenberg IH, Smith AD, Refsum H, et al. Biomarkers of nutrition…
Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial
This study of psilocybin assisted-therapy for TRD—to our knowledge, the first RCT in this population to assess feasibility…
Health system learning enables generalist neuroimaging models
Health system learning We define ‘health system learning’ as learning directly from uncurated data generated during routine clinical…
Generative AI-enabled clinical decision support system in primary care: a pragmatic, cluster-randomized trial
Design We conducted a pragmatic, multicenter, parallel-group cluster-randomized controlled trial across a network of 16 primary care facilities…
Evaluating the robustness and readiness of large frontier models in health AI applications
Singhal, K. et al. Large language models encode clinical knowledge. Nature 620, 172–180 (2023). Article CAS PubMed PubMed…
Dietary cholesterol activates a Ral-dependent pathway driving LDLR turnover
Goldstein, J. L. & Brown, M. S. A century of cholesterol and coronaries: from plaques to genes to…
Adiposity and cancer: epidemiology, mechanisms and future perspectives
NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis…
Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial
Trial details EMBRAZE was a randomized, double-blind, placebo-controlled, phase 2 trial (NCT06445075) conducted at seven sites in the…
MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial
Study conduct The trial was conducted from 19 May 2022 to 2 March 2026 (data cutoff date) in…
Advancing conversational diagnostic AI with multimodal reasoning
This work advances the diagnostic capabilities of the multimodal AMIE system4,5 by integrating multimodal perception, enabling it to…